Last reviewed · How we verify
multi-epitope melanoma peptide vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
multi-epitope melanoma peptide vaccine (multi-epitope melanoma peptide vaccine) — Craig L Slingluff, Jr.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| multi-epitope melanoma peptide vaccine TARGET | multi-epitope melanoma peptide vaccine | Craig L Slingluff, Jr | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- multi-epitope melanoma peptide vaccine CI watch — RSS
- multi-epitope melanoma peptide vaccine CI watch — Atom
- multi-epitope melanoma peptide vaccine CI watch — JSON
- multi-epitope melanoma peptide vaccine alone — RSS
Cite this brief
Drug Landscape (2026). multi-epitope melanoma peptide vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/multi-epitope-melanoma-peptide-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab